Comparing the Efficacy and Safety of Venetoclax Combined with Hypomethylating Agents Versus Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia Patients

Overview

Journal Blood Cancer J

Date 2025 Feb 11

PMID 39934109

Authors

Jingyi Shen

Meng Shan

Mengqian Chu

Yiming Cai

Jingwen Rui

Suning Chen

Depei Wu

Yang Xu

Affiliations

Soon will be listed here.

References

Borthakur G, Kantarjian H . Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 2021; 11(6):114. PMC: 8209225. DOI: 10.1038/s41408-021-00503-6. View

Wei A, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I . Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022; 140(25):2754-2756. DOI: 10.1182/blood.2022016963. View

Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S . Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016; 127(20):2451-9. PMC: 5457131. DOI: 10.1182/blood-2015-12-688705. View

Quan X, Deng J . Core binding factor acute myeloid leukemia: Advances in the heterogeneity of , , and mutations (Review). Mol Clin Oncol. 2020; 13(2):95-100. PMC: 7366242. DOI: 10.3892/mco.2020.2052. View

Kayser S, Kramer M, Martinez-Cuadron D, Grenet J, Metzeler K, Sustkova Z . Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. Haematologica. 2021; 107(4):836-843. PMC: 8968900. DOI: 10.3324/haematol.2021.278645. View

Qiu K, Liao X, Li Y, Huang K, Xu H, Fang J . Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16). BMC Cancer. 2023; 23(1):476. PMC: 10210276. DOI: 10.1186/s12885-023-10965-5. View

Opatz S, Polzer H, Herold T, Konstandin N, Ksienzyk B, Zellmeier E . Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia. Blood. 2013; 122(10):1761-9. DOI: 10.1182/blood-2013-01-476473. View

Haferlach C, Dicker F, Kohlmann A, Schindela S, Weiss T, Kern W . AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia. 2010; 24(5):1065-9. DOI: 10.1038/leu.2010.22. View

Paschka P, Du J, Schlenk R, Gaidzik V, Bullinger L, Corbacioglu A . Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood. 2012; 121(1):170-7. DOI: 10.1182/blood-2012-05-431486. View

10.

Zhao L, Melenhorst J, Alemu L, Kirby M, Anderson S, Kench M . KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice. Blood. 2011; 119(6):1511-21. PMC: 3286214. DOI: 10.1182/blood-2011-02-338210. View

11.

Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N . Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 2020; 4(1):66-75. PMC: 6960455. DOI: 10.1182/bloodadvances.2019000709. View

12.

Lo M, Cheng-Hong Tsai X, Lin C, Tien F, Kuo Y, Lee W . Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. Am J Hematol. 2023; 98(5):760-769. DOI: 10.1002/ajh.26892. View

13.

Kaburagi T, Yamato G, Shiba N, Yoshida K, Hara Y, Tabuchi K . Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. Haematologica. 2021; 107(3):583-592. PMC: 8883565. DOI: 10.3324/haematol.2020.269431. View

14.

DiNardo C, Pratz K, Pullarkat V, Jonas B, Arellano M, Becker P . Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2018; 133(1):7-17. PMC: 6318429. DOI: 10.1182/blood-2018-08-868752. View

15.

Pratz K, Jonas B, Pullarkat V, Thirman M, Garcia J, Dohner H . Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024; 99(4):615-624. DOI: 10.1002/ajh.27246. View